Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Nefazodone Treatment of Adolescent Depression: An Open-Label Study of Response and Biochemistry

Nefazodone Treatment of Adolescent Depression: An Open-Label Study of Response and Biochemistry Objective: The purpose of this study was to find whether nefazodone, effective in adult depression, might be similarly improve symptoms of adolescent depression. Secondary purpose was to relate platelet serotonin content to response, and to find if nefazodone's effect on platelet content was similar to that of the SSRIs. Method: 10 adolescents meeting DSMIV criteria for major depression received up to 400 mg of nefazodone for an eight week period. Response was assessed at baseline, 1, 2, 4, and 8 weeks by BDI and HDRS; platelet serotonin (5HT) content was obtained at baseline and final visit (for two dropouts, this was done at last visit, i.e., week 4). Results: In LOCF analysis, significant improvement was found in both HDRS (20.9 to 8.9, p = .01) and BDI (24.6 to 10.2, p = .01). Eight of nine patients with available data showed increases in platelet 5HT content (.02). In seven patients of eight completers with available data, there was a nonsignificant trend for patients with platelet 5HT baseline greater than 30 ng/108 platelets to show a greater change in HDRS than those with a baseline of less than 30 ng/108 platelets (p = .07). Conclusions: Further double-blind study of nefazodone in adolescent depression is indicated; nefazodone appears to increase platelet 5HT content. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Nefazodone Treatment of Adolescent Depression: An Open-Label Study of Response and Biochemistry

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/nefazodone-treatment-of-adolescent-depression-an-open-label-study-of-0Uc2SMYwie
Publisher
Springer Journals
Copyright
Copyright © 2000 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1009024214337
Publisher site
See Article on Publisher Site

Abstract

Objective: The purpose of this study was to find whether nefazodone, effective in adult depression, might be similarly improve symptoms of adolescent depression. Secondary purpose was to relate platelet serotonin content to response, and to find if nefazodone's effect on platelet content was similar to that of the SSRIs. Method: 10 adolescents meeting DSMIV criteria for major depression received up to 400 mg of nefazodone for an eight week period. Response was assessed at baseline, 1, 2, 4, and 8 weeks by BDI and HDRS; platelet serotonin (5HT) content was obtained at baseline and final visit (for two dropouts, this was done at last visit, i.e., week 4). Results: In LOCF analysis, significant improvement was found in both HDRS (20.9 to 8.9, p = .01) and BDI (24.6 to 10.2, p = .01). Eight of nine patients with available data showed increases in platelet 5HT content (.02). In seven patients of eight completers with available data, there was a nonsignificant trend for patients with platelet 5HT baseline greater than 30 ng/108 platelets to show a greater change in HDRS than those with a baseline of less than 30 ng/108 platelets (p = .07). Conclusions: Further double-blind study of nefazodone in adolescent depression is indicated; nefazodone appears to increase platelet 5HT content.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 8, 2004

References

  • Adolescents and school problems: depression, suicide, and learning disorders
    Weinberg, W; Emslie, G
  • Childhood depression and risk of suicide: a preliminary report of a longitudinal study
    Rao, U; Weissman, MM; Martin, JA; Hammond, RW
  • Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis
    Hazell, P; O'Connell, D; Heathcote, D; Robertson, J; Henry, D
  • An open naturalistic trial of fluoxetine in adolescents and young adults with treatment resistant major depression
    Boulos, C; Kutcher, S; Gardner, D; Young, E
  • Fluoxetine in tricyclic refractory depression in adolescents
    Ghaziuddin, N; Naylor, MW; King, CA
  • Fluoxetine in children and adolescents with mood disorders: a chart review of efficacy and adverse effects
    Jain, U; Birmaher, B; Garcia, M; Al-Shabbout, M; Ryan, N
  • Adolescent depression: a placebo-controlled fluoxetine treatment study and follow up
    Simeon, J; Dinicola, V; Ferguson, HB; Copping, W
  • A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression
    Emslie, GJ; Rush, AJ; Weinberg, WA; Kowatch, RA; Hughes, CW; Carmody, T; Rintelmann, J
  • Sertraline for major depression in children and adolescents: preliminary clinical experience
    Tierney, E; Paramjit, JT; Leinas, JF; Rosenberg, LA; Riddle, MA
  • A double-blind comparison of nefazodone, imipramine, and placebo in major depression
    Fontaine, R; Ontiveros, A; Elie, R; Kensler, TT; Roberts, DL; Kaplita, S; Ecker, JA; Faludi, G
  • Neurochemistry and paroxetine response in major depression
    Goodnick, PJ; Henry, J; Kumar, A
  • Sertraline in coexisting major depression and diabetes mellitus
    Goodnick, PJ; Kumar, A; Henry, JH; Buki, VMV; Goldberg, RB
  • Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationship to clinical outcome
    Celada, P; Dolera, M; Alvarez, E
  • Serotonin transport-blocking properties of nefazodone assessed by measurement of platelet serotonin
    Narayan, M; Anderson, G; Cellar, J; Mallison, RT; Price, LH; Nelson, JC
  • A modified HPLC technique for simultaneous measurement of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in cerebrospinal fluid, platelets, and plasma
    Kumar, AM; Kumar, M; Krishnaprasad, D.
  • Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder
    Bakish, D; Cavazzoni, P; Chudzik, J; Ravindran, A; Hrdina, PD